Author

F. D. Smith

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

J. D. Scott· 2 shared A. B. Francisco· 1 shared A. P. Massa· 1 shared B. C. Pascual· 1 shared C. G. Danko· 1 shared H. L. Kenerson· 1 shared J. Gordan· 1 shared K. Forbush· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. D. Scott

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma

S. M.-L. Lauer, M. H. Omar, M. G. Golkowski, H. L. Kenerson, B. C. Pascual, K. Forbush, F. D. Smith, J. Gordan, S.-E. M. Ong, R. S. Yeung, J. D. Scott

This study identifies BAG2 as a key player in DNAJ-PKAc-mediated chemotherapeutic resistance in fibrolamellar carcinoma by linking it to Hsp70 and Bcl-2.

bioRxiv · Jun 28, 2023Cancer Biology

Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal molecular mechanisms of oncogenesis and intrinsic drug resistance

T. A. Dinh, R. Sritharan, F. D. Smith, A. B. Francisco, R. K. Ma, R. P. Bunaciu, M. Kanke, C. G. Danko, A. P. Massa, J. D. Scott, P. Sethupathy

This study identifies aberrant enhancer activity in fibrolamellar carcinoma, revealing molecular mechanisms of oncogenesis and drug resistance, and suggests new therapeutic targets.

bioRxiv · Jan 18, 2020 · PreprintCancer Biology